Similar HbA1c reduction and hypoglycaemia with variable- vs fixed-time dosing of basal insulin peglispro in type 1 diabetes: IMAGINE 7 study

Diabetes, Obesity and Metabolism

Volumn 18, Issue , 2016, Pages 43-49

  Garg, S ^a   Selam, J L ^b   Bhargava, A ^c   Schloot, N ^d   Luo, J ^e   Zhang, Q ^e   Jacobson, J G ^e   Hoogwerf, Byron J ^e  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b Diabetes Research Center   (United States)

^c Iowa Diabetes and Endocrinology Center   (United States)

^d LILLY DEUTSCHLAND GMBH   (Germany)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

basal insulin peglispro; continuous glucose monitoring; variable time dosing

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN PEGLISPRO; ANTIDIABETIC AGENT; BASAL INSULIN PEGLISPRO; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN LISPRO; MACROGOL DERIVATIVE;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; ATRIAL FIBRILLATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEART PALPITATION; HUMAN; HYPOGLYCEMIA; INFECTION; INFESTATION; INFLUENZA; INJECTION SITE HYPERTROPHY; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INSULIN DEPENDENT DIABETES MELLITUS; LEG DISEASE; LIPOHYPERTROPHY; LOWER EXTREMITY MASS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOCTURNAL HYPOGLYCEMIA; OUTPATIENT CARE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUS CONGESTION; SINUSITIS; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; LEAST SQUARE ANALYSIS; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN LISPRO; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 84990243350     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12740     Document Type: Article

References (29)

1. Trence DL, Hirsch IB. Motherhood, apple pie, hemoglobin A(1C), and the DCCT. Endocr Pract. 2012;18:78–84.
2. Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010;12:288–298.
3. Bragd J, Adamson U, Backlund LB, Lins PE, Moberg E, Oskarsson P. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade? Diabetes Metab. 2008;34:612–616.
4. Kilpatrick ES, Rigby AS, Goode K, Atkin SL. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia. 2007;50:2553–2561.
5. Vora J, Heise T. Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review. Diabetes Obes Metab. 2013;15:701–712.
6. Sinha VP, Choi SL, Soon DK, et al. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. J Clin Pharmacol. 2014;54:792–799.
7. Sinha VP, Howey DC, Choi SL, Mace KF, Heise T. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16:344–350.
8. Rosenstock J, Bergenstal RM, Blevins TC, et al. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care. 2013;36:522–528.
9. Bergenstal RM, Rosenstock J, Arakaki RF, et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care. 2012;35:2140–2147.
10. Bergenstal RM, Lunt H, Franek E, et al. A Randomized, Double-Blind Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in Combination with Prandial Insulin Lispro, in Patients with Type 1 Diabetes: IMAGINE 3. Diabetes Obes Metab. 2016;18:1080–1087.
11. Blevins T, Pieber TR, Vega GC, Zhang S, Bastyr EJ III, Chang AM. Randomized Double-Blind Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in Combination with Prandial Insulin Lispro, in Patients with Type 2 Diabetes: IMAGINE 4. Diabetes Obes Metab. 2016;18:1071–1079.
12. Buse JB, Rodbard HW, Trescoli Serrano C, et al. A randomized clinical trial comparing basal insulin peglispro and insulin glargine in patients with type 2 diabetes mellitus previously treated with basal insulin: IMAGINE 5. Diabetes Care. 2016;39:92–100.
13. Davies MJ, Russell-Jones D, Selam J-L, et al. Basal insulin peglispro vs insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial. Diabetes Obes Metab. 2016;18:1054–1063.
14. Garg S, Dreyer M, Jinnouchi H, et al. A randomized clinical trial comparing basal insulin peglispro versus and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1 study. Diabetes Obes Metab. 2016;18(S2):25–33.
15. Grunberger G, Chen L, Rodriguez A, Tinahones FJ, Jacober SJ, Bue-Valleskey J. A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naive patients with type 2 diabetes: the IMAGINE 6 trial. Diabetes Obes Metab. 2016;18(S2):34–42.
16. Alberti KG, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–553.
17. Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med. 2008;25:442–449.
18. Bolli GB, Kerr D, Thomas R, et al. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care. 2009;32:1170–1176.
19. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–3086.
20. Bergenstal RM, Johnson M, Powers MA, et al. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care. 2008;31:1305–1310.
21. Qu Y, Luo J. Estimation of group means when adjusting for covariates in generalized linear models. Pharm Stat. 2015;14:56–62.
22. Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. Center for Drug Evaluation and Research, 2008: 27. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071624.pdf. Accessed August 1, 2016.
23. Buse JB, Rodbard HW, Trescoli Serrano C, et al. Superior HbA1c reduction with basal insulin peglispro (BIL) vs. insulin glargine (GL) alone or with oral antihyperglycemic medications (OAMs) in T2D patients (Pts) previously treated with basal insulin: IMAGINE 5. Diabetes. 2015;64:A249–A250.
24. Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98:1154–1162.
25. Hirsch I, Bode B, Courreges J-P, et al. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial. Diabetes Care. 2012;35:2174–2181.
26. Davies MJ, Gross JL, Ono Y, et al. Efficacy and safety of insulin degludec given as part of basal–bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes Obes Metab. 2014;16:922–930.
27. Vague P, Selam J-L, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care. 2003;26:590–596.
28. American Diabetes Association. Glycemic targets. Diabetes Care. 2015;38(Suppl):S33–40.
29. Ginsberg H, Cariou B, Orchard TJ, et al. Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in 6 IMAGINE trials. Diabetes Obes Metab. 2016;18:1088–1091.